Enovis (ENOV) closed the last trading session at $22.51, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $45.18 indicates a 100.7% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $6.91. While the lowest estimate of $33.00 indicates a 46.6% increase from the current price level, the most optimistic analyst expects th ...

Core Viewpoint - Enovis (ENOV) shares have increased by 13.1% in the past four weeks, closing at $25.79, with a mean price target of $45.55 indicating a potential upside of 76.6% according to Wall Street analysts [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $6.47, where the lowest estimate is $33.00 (28% increase) and the highest is $55.00 (113.3% increase) [2] - Analysts' consensus on price targets is often questioned, as their ability to set unbiased targets has been historically unreliable [3][7] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Group 2: Earnings Estimates and Market Sentiment - Analysts are optimistic about ENOV's earnings prospects, as indicated by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the past 30 days, one estimate has increased with no negative revisions, leading to an 11.2% rise in the Zacks Consensus Estimate for the current year [12] - ENOV holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Company Overview - Enovis operates as a global medical technology company focused on musculoskeletal health, leveraging a broad product portfolio and established distribution channels to serve healthcare professionals and institutions [5] - The company generates revenue through the sale of proprietary medical devices and solutions, targeting orthopedic specialists, surgeons, physical therapists, and other healthcare providers [7] Recent Developments - On February 18, 2026, Front Street Capital Management, Inc. reported an increase in its position in Enovis by 156,069 shares, valued at approximately $4.61 million [2] - The quarter-end value of Enovis's position rose by $3.40 million, reflecting both the additional shares and share price changes [2] - Enovis shares were priced at $25.42, down 36.5% over the past year, significantly underperforming the S&P 500's roughly 16% gain [6] Financial Performance - Enovis reported full-year revenue of $2.2 billion, representing a 7% increase, with organic growth of 6% [8] - Reconstructive sales climbed by 10%, and adjusted EBITDA reached $403 million [8] - Fourth quarter sales hit $576 million, with adjusted earnings per share of $0.95, exceeding expectations [8] Market Position and Strategy - The recent transaction by Front Street Capital Management indicates a measured turnaround strategy, with Enovis's allocation in the fund representing 1.37% of its 13F assets under management as of December 31, 2025 [6] - The company is guiding for revenue of up to $2.37 billion in 2026, with expectations of higher EBITDA [8][10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ ENOVIS CORPORATION (Exact name of registrant as specified in its charter ...

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [12] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [12][13] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [13][17] - Adjusted earnings per share rose to $3.30, up 16% due to gross margin expansion and reduced interest expenses [13] Business Line Data and Key Metrics Changes - The Recon segment achieved 8% organic growth, while the Prevention and Recovery (PNR) segment grew 4% organically [7][12] - In the fourth quarter, Recon grew 3% and PNR was flat, impacted by four fewer selling days compared to the previous year [8] - U.S. Recon experienced 6% organic growth in 2025, driven by double-digit growth in extremities and shoulders [8][9] - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees [9] Market Data and Key Metrics Changes - The overall market for PNR is believed to be growing closer to 2%, while the company achieved 4% organic growth in this segment [7] - The company noted that the U.S. hip and knee business is expected to see growth driven by new product launches and competitive conversions [9][16] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline [5] - A "One Enovis" operating mindset is being embraced to improve performance and standardize processes across the organization [6] - The company aims to achieve sustained above-market growth rates through innovation and cross-selling synergies [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's long-term plans and positive trajectory despite challenges such as tariffs and currency fluctuations [14][17] - The company expects 2026 to be another year of strong execution, with revenue guidance of $2.31 billion to $2.37 billion, reflecting mid-single-digit organic growth [18] - Management highlighted the importance of disciplined capital allocation and plans to reduce debt while investing in growth [54] Other Important Information - The company recorded a non-cash technical impairment of goodwill of $501 million, which does not impact liquidity or future operations [14] - The company plans to showcase new product innovations at the upcoming AAOS conference [10] Q&A Session Summary Question: Free cash flow conversion improvements - Management indicated that operational improvements and reduced integration-related costs will drive the expected increase in free cash flow conversion to 25% in 2026 [24][25] Question: ARVIS growth expectations - Management is excited about the phased rollout of ARVIS, aiming for domestic launch in the first half of 2026 and international rollout in the second half [27] Question: U.S. hip and knee business growth - Management expects the hip and knee expansion to benefit from new product launches and competitive conversions, with a focus on commercial execution [31] Question: Sustainability of PNR growth - Management believes there is significant opportunity for continued growth in the PNR segment, supported by geographic expansion and new product introductions [56] Question: Strategic synergies between segments - Management emphasized the importance of optimizing investments and collaboration between Recon and PNR segments to enhance commercial execution and operational efficiency [71][72]

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [12] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [12][13] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [13][17] - The company returned to positive free cash flow of $20 million in 2025, with a free cash flow conversion of 10% [8][17] Business Line Data and Key Metrics Changes - Organic revenue growth was 6%, with Recon achieving 8% organic growth, while Prevention and Recovery (PNR) grew 4% [7][12] - In the fourth quarter, Recon grew 3% organically, while PNR was flat [8] - U.S. Recon experienced 6% organic growth in 2025, driven by double-digit growth in extremities [8][9] - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees [9] Market Data and Key Metrics Changes - The market for Prevention and Recovery is believed to be growing closer to 2%, while the company achieved 4% organic growth in this segment [7] - The company noted that the fourth quarter had four fewer selling days than the prior year, impacting organic growth by 400 basis points [8] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline [5] - The "One Enovis" operating mindset aims to improve performance and standardize commercial processes across the organization [6] - The company plans to continue driving innovation, with a robust pipeline of new product introductions planned for the next 24 months [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's long-term plans and positive trajectory despite a dynamic operating environment [14] - The company expects 2026 to be another year of strong execution, with revenue guidance in the range of $2.31 billion to $2.37 billion [18] - Adjusted EBITDA is expected to improve by 50 basis points compared to the prior year, with a focus on driving gross margin improvements [19] Other Important Information - The company recorded a non-cash technical impairment of goodwill of $501 million, which does not impact liquidity or future operations [14] - The company is targeting a free cash flow conversion of 25% or more in 2026, with a pathway to 70%-80% in the future [25][33] Q&A Session Summary Question: Free cash flow conversion improvements - Management highlighted operational improvements and reduced integration-related costs as key drivers for the expected increase in free cash flow conversion [24][25] Question: ARVIS growth expectations - Management is excited about the rollout of ARVIS, expecting domestic rollout in the first half and international rollout in the second half of 2026 [27] Question: U.S. hip and knee business performance - Management indicated that the hip and knee expansion, along with ARVIS, could drive growth above the current range [31] Question: Cash flow and 510(k) filings - Management expects continued incremental improvements in cash flow conversion, despite the need for investments related to ARVIS [33] Question: Q4 cadence issues - Management clarified that Q4 performance was impacted by fewer selling days and did not reflect underlying market changes [36] Question: Gross margin sustainability - Management expects gross margins to continue improving due to positive product mix and productivity initiatives [39] Question: Strategic synergies between segments - Management emphasized the importance of collaboration and optimizing investments across business units to exploit synergies [71] Question: Portfolio shaping and divestitures - Management acknowledged the need for SKU rationalization and portfolio shaping to enhance growth and margin profiles [87]

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [11] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [11][12] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [12][15] - Adjusted earnings per share rose to $3.30, a 16% increase driven by gross margin expansion and reduced interest expenses [12] Business Line Data and Key Metrics Changes - The Recon segment achieved 8% organic growth, outperforming the market, while the Prevention and Recovery (PNR) segment grew 4% organically [5][11] - In the fourth quarter, Recon grew 3% and PNR was flat, impacted by four fewer selling days compared to the previous year [6][11] - The U.S. Recon segment grew 6% organically, with double-digit growth in extremities and solid performance in hips and knees [6][8] Market Data and Key Metrics Changes - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees and double-digit growth in extremities [8] - The company noted that the market for Prevention and Recovery is growing closer to 2%, while they achieved 4% organic growth in this segment [5] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline, aiming to build a more profitable and capital-efficient growth engine [4][5] - A "One Enovis" operating mindset is being embraced to improve performance and standardize commercial processes [5] - The company plans to continue driving innovation, with a robust pipeline of new product introductions planned for the next 24 months [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term plans and positive trajectory despite a dynamic operating environment [13] - The company expects 2026 to be another year of strong execution, with revenue guidance of $2.31 billion to $2.37 billion, reflecting mid-single-digit organic growth [17] - Management highlighted the importance of disciplined capital allocation and the goal of reducing debt while supporting growth initiatives [55] Other Important Information - The company returned to positive free cash flow of $20 million in 2025, with a target of over 25% free cash flow conversion in 2026 [6][16] - A non-cash technical impairment of goodwill of $501 million was recorded, but it does not impact liquidity or future operations [13] Q&A Session Summary Question: Free cash flow conversion improvements - Management indicated that operational improvements and reduced integration-related costs will drive the expected increase in free cash flow conversion [21][22] Question: ARVIS growth expectations - The rollout of ARVIS is planned in phases, with domestic launch in the first half of 2026 and international rollout in the second half [25][26] Question: U.S. hip and knee business outlook - Management expressed optimism about the hip and knee expansion, particularly with new product launches like Nebula and OrthoDrive [30] Question: Cash flow conversion trajectory - Management expects continued incremental improvements in cash flow conversion over the next several years, despite some initial investments required for new product launches [32] Question: Market dynamics and Q1 expectations - Management noted that Q1 2026 will have fewer selling days, but overall business performance is expected to align with expectations [35][37] Question: Gross margin sustainability - Management anticipates further gross margin improvements driven by product mix and productivity initiatives [39][40] Question: Portfolio shaping and divestitures - Management acknowledged the need for ongoing portfolio shaping, including SKU rationalization and potential divestitures to enhance growth and margin profiles [91][92]

分组1 - Enovis reported quarterly earnings of $0.95 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, but down from $0.98 per share a year ago, resulting in an earnings surprise of +17.28% [1] - The company posted revenues of $575.76 million for the quarter, missing the Zacks Consensus Estimate by 1.41%, compared to $560.97 million in the same quarter last year [2] - Enovis has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 16.2% since the beginning of the year, while the S&P 500 has gained 1.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.80 on revenues of $579.42 million, and for the current fiscal year, it is $3.26 on revenues of $2.35 billion [7] - The Medical Info Systems industry, to which Enovis belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, indicating potential challenges ahead [8]

Fourth Quarter 2025 Results February 26, 2026 © 2026 Enovis Corporation This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward- looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements and are based on E ...

Core Viewpoint - Enovis Corporation reported its financial results for Q4 and the full year of 2025, highlighting a net sales growth but significant losses due to goodwill impairment charges. Financial Results Summary Fourth Quarter 2025 - Net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for the year amounted to $2.2 billion, marking a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, which included a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the full year was reported at $403 million [6] Management Commentary - The CEO of Enovis stated that 2025 was a year of meaningful operational progress, with advancements in integration priorities and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it moves into 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, reflecting 4-6% organic revenue growth [8] - Adjusted EBITDA is anticipated to be between $425 million and $435 million, with adjusted earnings per share projected to be between $3.52 and $3.73 [8]